Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07270562

ORbital Atherectomy for Lesion Preparation in Patients With Chronic Limb-threatening ischEmia

ORACLE is a Europe-wide study that will follow 250 people with critical limb-threatening ischemia (CLTI). It aims to see how well orbital atherectomy (OA) works in real-life practice. OA is a procedure that uses a tiny spinning tool to gently remove hard calcium from inside an artery, helping to open the vessel so other treatments-like balloons or stents-can work better. The study focuses on people who have heavily calcified arteries in the femoropopliteal or infrapopliteal areas of the leg.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Rutherford classification category ≥4;
  • Treatment of femoropopliteal or infrapopliteal calcified lesions with OA using the Stealth 360 peripheral OA System;
  • Calcification of target lesions must be visible on fluoroscopy or CT-angiography;
  • Patients competent and willing to provide informed consent.

Exclusion criteria

  • Minors and other vulnerable populations who may not be able to give informed consent freely or for whom participation is not essential to the study (incapacitated and unconscious individuals, persons deprived of liberty, pregnant and breastfeeding women, etc.);
  • Inadequate inflow (>30% stenosis) following optimization;
  • Insufficient direct outflow (less than 1 run-off vessel);
  • Endovascular procedure(s) on the treatment site within 4 weeks before index procedure;
  • Patients planned to receive an above ankle amputation of the target limb;
  • Patients enrolled in RESCUE (ClinicalTrials.gov ID NCT07270575).

Treatment and study plan

Stealth 360™ Peripheral Orbital Atherectomy System from Abbott

Device

The Stealth 360™ Peripheral Orbital Atherectomy System uses a diamond-coated, eccentrically mounted crown with bi-directional capabilities that treat a wide range of vessels, enabling single device treatment of multiple lesions and vessel sizes.

Other names: Orbital Atherectomy, Orbital Atherectomy System

Primary outcomes

  1. Number of lesions with ≤30% residual stenosis after completion of full planned procedure

    Time frame: Immediately after procedure completion

    Defined as residual stenosis ≤30%, immediately after completion of full planned procedure (OA + any planned adjunctive intervention(s)).

Secondary outcomes

  1. Number of lesions with ≤30% residual stenosis after any unplanned endovascular intervention(s)

    Time frame: Immediately after procedure completion

    Defined as residual stenosis ≤30% immediately after completion of additional unplanned endovascular intervention(s) (any endovascular procedure that was not part of the primary procedure plan).

  2. Need for unplanned bailout stenting

    Time frame: Immediately after procedure completion

    Defined as any stent placement that was not part of the primary procedure plan.

  3. Number of participants free from Clinically-Driven Target Lesion Revascularization (CD-TLR)

    Time frame: 12 and 24 months

    Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.

  4. CD-TLR-free survival

    Time frame: Until the end of the follow-up period of 2 years

    Defined as time between first OA procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.

  5. Clinical response using Rutherford classification categories

    Time frame: 12 and 24 months

    The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss.

  6. Wound status

    Time frame: 12 and 24 months

    Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening).

  7. Freedom from amputation of the target limb

    Time frame: 12 and 24 months

    Defined as absence of any amputation of the target limb (above ankle).

  8. Amputation-free survival

    Time frame: Until the end of the follow-up period of 2 years

    Defined as time between first OA procedure and above-ankle amputation of the target limb.

  9. Overall survival

    Time frame: Until the end of the follow-up period of 2 years

    Defined as the time between the first OA procedure and death of any cause.

  10. Patient-reported health-related quality-of-life

    Time frame: Baseline, 6, 12 and 24 months post treatment

    Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD.

  11. Frequency and severity of procedural complications and other adverse events

    Time frame: Within 30 days after the OA procedure

    Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe.

  12. Clinical response using ankle-brachial index (ABI)

    Time frame: 12 and 24 months

    The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease.

  13. Clinical response using toe pressure

    Time frame: 12 and 24 months

    The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion.

  14. Clinical response using WIfi (wound, ischemia and foot infection) score

    Time frame: 12 and 24 months

    The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization.

Study contacts

Contact information is provided by the study sponsor or research team.

Claire Poulet, PhD

CONTACT

[email protected]

+41 79 385 16 78

Dhwani S. Korde, PhD

CONTACT

[email protected]

+4367762942469

Sponsors and collaborators

Lead sponsor

Cardiovascular and Interventional Radiological Society of Europe

Other

Collaborators

  • Abbott

Registry information

Acronym: ORACLE

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Dec 8, 2025
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.